Flk-1+ Mesenchymal Stem Cells Aggravate Collagen-induced Arthritis by Up-regulating Interleukin-6

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2009 Dec 17

PMID 20002448

Citations 42

Authors

B Chen

J Hu

L Liao

Z Sun

Q Han

Z Song

R C Zhao

Affiliations

Soon will be listed here.

Abstract

The immunomodulatory ability of mesenchymal stem cells (MSCs) may be used to develop therapies for autoimmune diseases. Flk-1(+) MSCs are a population of MSCs with defined phenotype and their safety has been evaluated in Phase 1 clinical trials. We designed this study to evaluate whether Flk-1(+) MSCs conferred a therapeutic effect on collagen-induced arthritis (CIA), an animal model of rheumatic arthritis, and to explore the underlying mechanisms. Flk-1(+) MSCs, 1-2 x 10(6), were injected into CIA mice on either day 0 or day 21. The clinical course of arthritis was monitored. Serum cytokine profile was determined by cytometric bead array kit or enzyme-linked immunosorbent assay. Flk-1(+) MSCs and splenocytes co-culture was conducted to explore the underlying mechanisms. Flk-1(+) MSCs did not confer therapeutic benefits. Clinical symptom scores and histological evaluation suggested aggravation of arthritis in mice treated with MSCs at day 21. Serum cytokine profile analysis showed marked interleukin (IL)-6 secretion immediately after MSC administration. Results of in vitro culture of splenocytes confirmed that the addition of Flk-1(+) MSCs promoted splenocyte proliferation and increased IL-6 and IL-17 secretion. Moreover, splenocyte proliferation was also enhanced in mice treated with MSCs at day 21. Accordingly, MSCs at low concentrations were found to promote lipopolysaccharide-primed splenocytes proliferation in an in vitro co-culture system. We propose that Flk-1(+) MSCs aggravate arthritis in CIA model by at least up-regulating secretion of IL-6, which favours Th17 differentiation. When Flk-1(+) MSCs are used for patients, we should be cautious about subjects with rheumatoid arthritis.

Citing Articles

Adipose-Derived Mesenchymal Stem Cells from Arthritis Patients: Differential Modulation of CD4⁺ T Cell Activation and Cytokine Production.

Oldak M, Kurowska W, Plebanczyk M, Janicka I, Radzikowska A, Skalska U Med Sci Monit. 2024; 30:e945273.

PMID: 39543859 PMC: 11575092. DOI: 10.12659/MSM.945273.

Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.

Kotani T, Saito T, Suzuka T, Matsuda S Inflamm Regen. 2024; 44(1):35.

PMID: 39026275 PMC: 11264739. DOI: 10.1186/s41232-024-00348-z.

Genome-Edited Human MSCs Exhibit Robust Anti-Arthritogenicity in Collagen-Induced Arthritis.

Chae D, Han S, Kim S Int J Mol Sci. 2024; 25(8).

PMID: 38674027 PMC: 11050354. DOI: 10.3390/ijms25084442.

Insensitive Effects of Inflammatory Cytokines on the Reference Genes of Synovial Fluid Resident-Mesenchymal Stem Cells Derived from Rheumatoid Arthritis Patients.

Bok E, Kim S, Thakur G, Choe Y, Oh S, Hwang S Int J Mol Sci. 2023; 24(20).

PMID: 37894839 PMC: 10607131. DOI: 10.3390/ijms242015159.

Anti-Arthritogenic Property of Interleukin 10-Expressing Human Amniotic MSCs Generated by Gene Editing in Collagen-Induced Arthritis.

Chae D, Park Y, Kim S Int J Mol Sci. 2022; 23(14).

PMID: 35887258 PMC: 9320257. DOI: 10.3390/ijms23147913.

References

Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao R . Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun. 2005; 332(2):370-9. DOI: 10.1016/j.bbrc.2005.04.135. View

Korn T, Mitsdoerffer M, Croxford A, Awasthi A, Dardalhon V, Galileos G . IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008; 105(47):18460-5. PMC: 2587589. DOI: 10.1073/pnas.0809850105. View

Spaggiari G, Capobianco A, Becchetti S, Mingari M, Moretta L . Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2005; 107(4):1484-90. DOI: 10.1182/blood-2005-07-2775. View

Jiang X, Zhang Y, Liu B, Zhang S, Wu Y, Yu X . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005; 105(10):4120-6. DOI: 10.1182/blood-2004-02-0586. View

Eddahri F, Denanglaire S, Bureau F, Spolski R, Leonard W, Leo O . Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood. 2008; 113(11):2426-33. PMC: 2656270. DOI: 10.1182/blood-2008-04-154682. View

Fang B, Song Y, Liao L, Han Q, Zhao R . Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 38(5):389-90. DOI: 10.1038/sj.bmt.1705457. View

Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M . Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007; 16(5):719-31. DOI: 10.1089/scd.2007.0065. View

Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z . Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng. 2005; 11(1-2):110-9. DOI: 10.1089/ten.2005.11.110. View

Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

10.

Rasmusson I, Le Blanc K, Sundberg B, Ringden O . Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol. 2007; 65(4):336-43. DOI: 10.1111/j.1365-3083.2007.01905.x. View

11.

Lubberts E, Koenders M, van den Berg W . The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005; 7(1):29-37. PMC: 1064899. DOI: 10.1186/ar1478. View

12.

Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P . Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997; 158(11):5507-13. View

13.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

14.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

15.

Chiocchia G, Bessis N, Batteux F, Muller S, Huang S, Boissier M . High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol. 1997; 158(11):5501-6. View

16.

Stuart J, Cremer M, Townes A, Kang A . Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982; 155(1):1-16. PMC: 2186578. DOI: 10.1084/jem.155.1.1. View

17.

Zhang W, Ge W, Li C, You S, Liao L, Han Q . Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004; 13(3):263-71. DOI: 10.1089/154732804323099190. View

18.

Aksu A, Horibe E, Sacks J, Ikeguchi R, Breitinger J, Scozio M . Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol. 2008; 127(3):348-58. DOI: 10.1016/j.clim.2008.02.003. View

19.

Zheng Z, Li X, Ding J, Jia J, Zhu P . Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford). 2007; 47(1):22-30. DOI: 10.1093/rheumatology/kem284. View

20.

Wooley P, Luthra H, Singh S, Huse A, Stuart J, David C . Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc. 1984; 59(11):737-43. DOI: 10.1016/s0025-6196(12)65583-9. View